A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants

Jay M. Sosenko, Jay S. Skyler, Jerry P. Palmer, Jeffrey P. Krischer, David Cuthbertson, Liping Yu, Desmond A. Schatz, Tihamer Orban, George Eisenbarth

Research output: Contribution to journalArticle

17 Scopus citations


OBJECTIVE - We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS - Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS - Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline. CONCLUSIONS - IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

Original languageEnglish (US)
Pages (from-to)2435-2437
Number of pages3
JournalDiabetes care
Issue number11
StatePublished - Nov 1 2011


ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this